Smith+Nephew is the first orthopaedics company to receive FDA 510 (k) clearance for a revision indication using a robotics-assisted platform.

Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a ...

Smith+Nephew now offers the first and only robotic revision indication in the US with RI.KNEE ROBOTICS – combining the CORI ™ Surgical System and LEGION ™ RK System with OXINIUM ™ Technology.

Smith & Nephew made considerable progress with its robot placements in the quarter, and the expanding installed base has shown up in knee replacements—more than 25% of third-quarter knee ...

Smith+Nephew SNN recently launched its Real Intelligence brand of enabling technology solutions as well as its next-generation handheld robotics platform, the CORI Surgical System, in Canada.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the CENTRIO ...

Narrow-moat Smith & Nephew posted decent third-quarter trading results that largely fell within our expectations, and we’re leaving our fair value estimate unchanged. The company delivered ...

Smith+Nephew’s new CATALYSTEM Primary Hip System is designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-marketing agreement with JointVue for its patented OrthoSonic™ 3D Surgery Planning ...